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Human aortic smooth muscle cells
Migration
InvasionAdvanced glycation end-products (AGEs) play key roles in the development of diabetic vascular complications by
activating the proliferation and migration of vascular smooth muscle cells. Here, we identiﬁed an increase of
the migratory properties of human aortic smooth muscle cells (HASMC) through AGE-induced expression of
lipocalin-2 (LCN2). Because the AGE-elicited expression of LCN2 was diminished by an antibody against the
AGE receptor (RAGE), diphenylene iodonium (DPI), N-acetyl cysteine, LY294002, and SP600125, we suggest
that AGEs enhance the expression of LCN2 via a RAGE-NADPH oxidase-reactive oxygen species pathway, leading
to the phosphorylation of PI3K-Akt and JNK in HASMCs. In addition, a chromatin immunoprecipitation assay and
promoter assay revealed that CCAAT/enhancer binding protein β is crucial for AGE-induced expression of LCN2.
However, any other AGE-related signaling pathway, including ERK1/2, p38, NF-κB, and AP-1, did not affect the
AGE- induced expression of LCN2. Knockdown of LCN2 expression by shRNA showed that AGE-elicited LCN2
expression enhanced the invasive and migratory properties of HASMCs, but showed no effect on cell proliferation.
Considering the importance of HASMCmigration in the development of atherosclerosis, our study provides a novel
insight into diabetic vascular complications.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis plays a pivotal role in cardiovascular morbidity and
mortality in diabetic patients by causing coronary artery disease, stroke,
and diabetic foot ulcers [1]. Although diverse pathologic factors
have been implicated in the cardiovascular complications of diabetes,
advanced glycation end-products (AGEs), which are the products of
non-enzymatic glycation of proteins, are known as key players in the
development of diabetic vascular complication [2]. AGEs bind to diverse
receptors, including the receptor for AGEs (RAGE), class A, class B, type I
and type II scavenger receptors, CD36, AGE receptor 1, AGE receptor 2,
and galectin-3 [3–5]. RAGE is mainly associated with increases in
oxidative stress, growth, and inﬂammatory effects, whereas the other
receptors are involved in AGE detoxiﬁcation, negative regulation of
RAGE effects, and supporting inﬂammation [3,4,6]. AGEs accumulate
in the plasma and increase vascular inﬂammation by interacting with
RAGEonﬁbroblasts, hepatic stellate cells,monocytes, vascular endothelial
cells, and vascular smooth muscle cells (VSMCs) [5,7–10]. Numerous
studies have reported that AGEs induce the proliferation [7,11],
calciﬁcation [12,13], adhesion [14], and migration [15] of VSMCs.ne, School of Korean Medicine,
gsangnam-do 626-870, Republic
ights reserved.Among the pathological processes related to atherosclerosis, VSMC
migration into the intima plays an important role in the initial step of
plaque formation [16]. Although the migratory activities of VSMCs are
regulated by AGEs [17], the molecular mechanisms underlying this
phenomenon are not fully understood.
Lipocalin-2 (LCN2) is also known as neutrophil gelatinase-associated
lipocalin, and siderocalin is a 25-kDa glycoprotein belonging to the
lipocalin family [18]. Because LCN2 binds to small lipophilic molecules
such as bacteria-derived formylpeptides, leukotriene [19], and catechol-
type siderophores [20], it was initially considered as a modulator of the
innate immune system. In addition, LCN2 is involved in allosteric
activation and degradation protection of matrix metalloproteinase
(MMP)-9 [21,22]. Recent studies suggest that LCN2 also plays an
important role in cell homeostasis, including morphogenesis [23],
epithelial-to-mesenchymal transition [24], iron trafﬁcking [25], and
tumor growth [26]. Previous studies of LCN2 have been focused on
its role as a biomarker in diverse diseases, including anemia [27],
metabolic disease [28,29], inﬂammatory bowel disease [30], acute renal
injury [31,32], and diabetic nephropathy [33–36]. In addition, elevated
LCN2 expression is related to several vascular diseases, including
atherosclerosis [37,38], myocardial infarction [38], and plaque
instability [39]. However, the association of LCN2 with diabetic
vascular complications is still unclear.
Here, we report for the ﬁrst time that AGEs induce LCN2 expression
in human aortic smooth muscle cells (HASMCs) through activation of
CCAAT/enhancer binding proteinβ (C/EBPβ), but not NF-κB. In addition,
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the migration and invasion of HASMCs.2. Materials and methods
2.1. Materials
Antibodies against the p65 subunit of NF-κB (F-6), c-fos (D-1), c-jun
(H-79), C/EBP-β (C-19), lamin B (C-5), RAGE (A11), paxillin (H-114),
and vinculin (H-300) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). An antibody against LCN2 (ab23477) was purchased
from Abcam (Cambridge, MA). BAY 11-7082 (NF-κB inhibitor) and an
antibody against β-actin was purchased from Sigma–Aldrich (St. Louis,
MO). Inhibitors of speciﬁc signaling pathways, including LY294002
(PI3K inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 inhibitor),
and SP600125 (JNK inhibitor), were purchased from Merck Millipore
(Billerica, MA). All other chemicals and reagents, including human
serum albumin (HSA) and glycated human albumin (AGEs), were
obtained from Sigma–Aldrich unless otherwise indicated.2.2. Cell culture
HASMCs were purchased from BioWhittacker (San Diego, CA) and
cultured in smooth muscle cell growth medium-2 (SmGM-2) containing
10% fetal bovine serum (FBS; Sigma-Aldrich), 2 ng/mL human basic
ﬁbroblast growth factor, 0.5 ng/mL human epidermal growth factor,
50 mg/mL gentamicin, 50 mg/mL amphotericin-B, and 5 mg/mL bovine
insulin. For all experiments, early passage HASMCs were grown to
80–90% conﬂuence and thenquiescencewas inducedby serumstarvation
(0.1% FBS) for at least 24h.2.3. Gelatin zymography
Cells were grown in serum-free medium with the indicated
concentrations of AGEs for 24h. Conditioned media were prepared
in a sample buffer containing 62.5mMTris–HCl (pH6.8), 10% glycerol, 2%
SDS, and0.00625% (w/v) bromophenol bluewithout boiling. The samples
were loaded in an acrylamide/bisacrylamide (29.2:0.8) separating gel
containing 0.1% (w/v) gelatin, and then electrophoresed at 4 °C. The
gels were soaked twice in 0.25% Triton X-100 for 30 min at room
temperature and then incubated at 37 °C for 20 h in incubation buffer
containing 50 mM Tris–HCl (pH 7.6), 20 mM NaCl, 5 mM CaCl2, and
0.02% Brij-58. The gels were then stained for 30 min in 0.1% (w/v)
Coomassie blue R-250 solubilized in 30% methanol and 10% acetic acid.2.4. Reverse transcription-polymerase chain reaction (RT-PCR) and
quantitative real-time RT-PCR (qRT-PCR)
Total RNAwas extracted from cells using TRIzol (Invitrogen, Carlsbad,
CA). Onemicrogramof total RNA fromeach samplewas then subjected to
reverse transcription with oligo-dT primers by using AccuPower RT-
PreMix (Bioneer, Daejeon, Korea). The cDNA was ampliﬁed by PCR
using AccuPower PCR-PreMix (Bioneer). The primers used to amplify
LCN2 and β-actin are shown in Supplementary Table 1. Ampliﬁed DNA
was separated on 1.5% agarose gels and visualized under UV light.
qRT-PCRwas performed using iTaq™Universal SYBR®Green Supermix
(Bio-Rad) on a Bio-Rad iQ™ 5 Multicolor Real-Time PCR Detection
System according to the manufacturer's instructions. Primer sequences
for qRT-PCR were as follows: LCN2, forward 5′-TGATCCCAGCCCCACCT-
3′ and reverse 5′-CCACTTCCCCTGGAATTGGT-3′; β-actin, forward 5′-
CAAGAGATGGCCACGGCTGCT-3′ and reverse 5′-TCCTTCTGCATCCTGT
CGGCA-3′.2.5. Western blot analysis
Protein extracts from harvested cells were prepared using RIPA
buffer (Cell Signaling, Danvers, MA) containing a protease inhibitor
cocktail tablet (Roche, Mannheim, Germany). Nuclear proteins were
extracted using an NE-PER Nuclear and Cytoplasmic Extraction
Reagents Kit (Pierce, Rockford, IL). Equal quantities of proteins
were size fractionated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then electrotransferred to nitrocellulose
membranes. Themembraneswere incubatedwith target protein-speciﬁc
primary antibodies and horseradish peroxidase-conjugated secondary
antibodies. After incubation, speciﬁc bands of interest were detected by
ECL Plus (GE Healthcare, Uppsala, Sweden).
2.6. Cell growth determination
HASMCs were seeded in 6-well culture plates at a density of 1×106
cells perwell in SmGM-2 supplementedwith 10% FBS and then cultured
for 24 h. The cells were treated with or without AGEs (200 μg/mL) for
72 h. Then, the cells were harvested, and the cell growth rates were
determined using the Countess® Automated Cell Counter (Invitrogen).
2.7. Plasmid construction and luciferase assay
A 1-kb fragment of the LCN2 promoter region was ampliﬁed from
human genomic DNA by PCR and then cloned into a pGL4.17 vector
(Promega, Fitchburg, WI). The sequence was veriﬁed by automated
sequence analysis. Potential transcription factor binding sites were
analyzed by Transcription Element Search System (TESS; http://www.
cbil.upenn.edu/tess). Site-directed mutants of two different C/EBP sites
were constructed using a QuikChange II XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA). The mutations were veriﬁed by sequence
analysis. The primers for cloning and mutating the LCN2 promoter
are listed in Supplementary Table 1. The promoter plasmids were
co-transfected with pCMV-β-galactosidase reporter plasmids (Clontech,
Mountain View, CA) into HASMCs by using WelFect-EX™ PLUS reagent
(WelGENE, Daegu, Korea). The cells were cultured for 24h with medium
containing 10% FBS, stimulatedwith AGEs for 24h, and then collected and
lysed by sonication in lysis buffer (25mM Tris-phosphate, pH7.8, 2mM
EDTA, 1% Triton X-100, and 10% glycerol). The cell lysates were assayed
for luciferase activity using a luciferase assay kit (Promega) with
normalization to β-galactosidase activity as the control.
2.8. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using a ChIP assay kit (Upstate, Utica, NY)
according to the manufacturer's protocol. DNA-binding proteins were
cross-linkedwithDNAand then incubated in SDS lysis buffer containing
protease inhibitor cocktail tablet. DNA was sheared to 200–500 bp
fragments by 30-s sonication pulses using a VC100 sonicator (Sonics &
Materials, Newtown, CT). The chromatin solution was precleared with
salmon DNA/protein Agarose 50% slurry (Upstate) for 30 min at 4 °C.
The precleared supernatant was incubated overnight at 4 °C with anti-
NF-κB, anti-C/EBP-β, anti-c-fos, and isotypic IgG antibodies. Precipitated
DNA and input genomic DNA were ampliﬁed by PCR with primers
shown in Supplementary Table 1. The PCR products were separated
on a 2% agarose gel and visualized under UV light.
2.9. Knockdown of LCN2 by shRNA
Five human pLKO.1 lentiviral vectors encoding shRNAs targeting the
LCN2 gene were obtained from Open Biosystems (Thermo Scientiﬁc,
Waltham, MA). Transfection was performed using WelFect-EX™ PLUS
reagent (WelGENE) and selected with puromycin (2 μg/mL) to obtain
10 clones. The knockdown efﬁciency of the siRNAs against LCN2
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blot analysis.2.10. Flow cytometric analysis of DNA content
Cells were harvested, centrifuged (2500 ×g, 4 °C, 10 min), and
washed twice in PBS. The cell pellet was gently resuspended in 100 μL
PBS, and 200 μL PBS containing 10% ethanol/5% glycerol was then
added to the cells, followed by 200 μL PBS containing 50% ethanol/5%
glycerol. The cell suspension was then incubated on ice for 5min. One
milliliter of PBS containing 70% ethanol/5% glycerol was added to the
cell suspension, followed by incubation at 4 °C overnight. Then, the
cell suspension was washed with PBS and resuspended with 250 μL
of 1.12% sodium citrate buffer (pH 8.45) containing 12.5 μg RNase
(Sigma–Aldrich). After further incubation at 37 °C for 30 min, cellular
DNA was stained with 250 μL propidium iodide (50 μg/mL) for 30min
at room temperature. To assess the relative DNA content, the stained
cells were analyzed by a FACSCanto II (BD Biosciences, San Jose, CA)
with BD FACSDiva™ software.2.11. Migration and invasion assays
The migration assay was performed using 24-well plates containing
polycarbonate ﬁlter (8-μm pore size) inserts (Corning Inc., NY). For the
invasion assay, the upper sides of the ﬁlters were coated with 100μL
of 0.2% gelatin. SmGM-2 containing 1% FBS with or without AGEs
(200 μg/mL) was added to the lower chamber. HASMCs in SmGM-2
containing 1% FBS (5 × 104 cells/200 μL) were then added to the
upper chambers in the presence or absence of AGEs (200 μg/mL).
The cells were incubated at 37 °C with 5% CO2 for 24 h. After
incubation, the ﬁlter inserts were removed from the wells, and
the cells on the upper side of the ﬁlter were removed using cotton
swabs. The remaining cells on the ﬁlters were ﬁxed, stained with
hematoxylin and eosin, and mounted on microscope slides. The cells
located on the underside of the ﬁlter were counted as migrating or
invading cells.2.12. Confocal microscopic observation
The cells maintained on glass coverslips were stimulated with
AGEs (200 μg/mL). After 12 or 24 h, the cells were ﬁxed with 4%
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100 in
PBS. After 1 h of incubation with blocking buffer (5% BSA in PBS), the
cells were incubated with anti-C/EBPβ, -paxillin, or -vinculin antibodies
(1:100) for 1h, followed by1h of incubationwith Texas Red-conjugated
anti-rabbit IgG or ﬂuorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG (1:1000; Invitrogen, Carlsbad, CA). After washing with cold
PBS, actin was stained with Texas Red X phalloidin (Invitrogen), and
the cells were mounted on glass slides using VECTASHIELD Mounting
Medium(Vector Lab., Burlingame, CA). Fluorescent imageswere obtained
using a ZEISS LSM700 laser scanning confocal microscope (Carl Zeiss,
Oberkochen, Germany).2.13. Statistical analysis
The data from proliferation, migration, invasion, and promoter assays
are represented as the fold differences compared to the control and
expressed as the mean± SD. The differences between the mean values
of 2 groups were determined by one-way analysis of variance with the
post-hoc Dunnett's comparison. The minimum signiﬁcance level was set
at a P value of 0.05. All experiments were performed at least 3 times
independently.3. Results
3.1. AGEs enhance LCN2 expression, proliferation, andmigration of HASMCs
AGEs have been reported to be an inducer of intimal hyperplasia [40]
and VSMC migration [15], which is important in the pathogenesis of
diabetes-related atherosclerosis. MMPs, especially MMP-2 and -9, have
been reported to play key roles in themigration of VSMCs into the intima
[41]. Thus, we considered that MMP-2 and -9 were, at least partially,
responsible for the AGE-related migration of VSMCs. Surprisingly, the
gelatin zymography data revealed that the expression of MMP-2 and -9
was not markedly changed by AGE treatment in HASMCs (Fig. 1A). The
results from RT-PCR and western blot analyses of MMP-2 and -9
expression were the same as those obtained from gelatin zymography
(data not shown). However, gelatin zymography showed that a protein
band at about 130 kDa was increased by AGE treatment. In previous
reports, this band was revealed to be a heterodimeric complex of
MMP-9 and LCN2 [21,22]. Thus, we conﬁrmed the expression of LCN2
mRNA and protein elicited by AGE treatment by using RT-PCR, western
blot analysis, and qRT-PCR (Fig. 1A). Next, we examined the effect of
AGEs on the proliferation and migration of HASMCs. The results revealed
that AGEs signiﬁcantly increased the proliferation and migration of
HASMCs (Fig. 1B and C).
3.2. AGE-enhanced LCN2 expression is related to the RAGE-NADPHoxidase-
reactive oxygen species (ROS) pathway, leading to activation of PI3K-Akt
and JNK signal transduction in HASMCs
Circulating AGEs stimulate cells via binding to its receptor expressed
on target cells, and subsequently activating NADPH oxidase activity
and ROS production [9]. Thus, we examined whether this pathway
is responsible for AGE-stimulated expression of LCN2 by using speciﬁc
antibodies or inhibitors. Our results showed that treatment with an
anti-RAGE antibody, which was speciﬁc for the extracellular domain,
diminished the expression of LCN2 mRNA and protein in AGE-treated
HASMCs, but an isotypic anti-IgG antibody did not show such an effect
(Fig. 2A). In addition, diphenylene iodonium (DPI), a known NADPH
oxidase inhibitor, or N-acetyl cysteine, a ROS inhibitor, also decreased
the expression of LCN2 mRNA and protein (Fig. 2B).
Mitogen-activated kinases (MAPKs) and PI3K-Akt are downstream
signaling pathways of NADPH oxidase-ROS, and are involved in the
proliferation and migration of VSMCs [7,42]. Therefore, we examined
the relationship of these signaling molecules, including Akt, JNK, ERK,
and p38, with AGE-induced expression of LCN2 mRNA and protein in
HASMCs. Our data showed that AGEs increased the phosphorylation of
these molecules (Fig. 2C and D). However, as shown in Fig. 2E, treatment
with speciﬁc inhibitors showed that activation ofAkt and JNK, but not ERK
or p38, was required for AGE-induced expression of LCN2 mRNA and
protein. In addition, treatment with BAY 11-7082, a speciﬁc inhibitor of
NF-κB, also showed no effect on LCN2 expression.
3.3. Transactivation of C/EBPβ is responsible for AGE-induced LCN2
expression
Previous studies [18,43] and our analysis by TESS indicateNF-κB, AP-
1, and C/EBPβ binding sites in the promoter region of the human LCN2
gene (Fig. 3A). As shown in Fig. 2D, Akt and JNK were activated from
30 min to 3 h after AGE treatment. Thus, we examined nuclear
translocation of the p65 subunit of NF-κB, c-fos, c-jun, and C/EBPβ. The
data revealed that the nuclear translocation of C/EBPβ was remarkably
increased from 3 to 6 h after AGE treatment. Translocation of p65
was slightly increased from 1 h, but localization of c-jun and c-fos
was almost unchanged by AGE treatment (Fig. 3B). Furthermore,
immunoﬂuorescence staining for C/EBPβ showed that AGEs clearly
induced translocation of C/EBPβ into the nucleus (Fig. 3C).
Fig. 1. AGEs enhance LCN2 expression, proliferation, and migration of HASMCs. The HASMCs were treated with HSA or the indicated concentrations of AGEs in serum-free medium for
24h. (A) The supernatants were collected for gelatin zymography and total RNA and proteinswere extracted fromHSA- or AGE-treatedHASMCs. Heterodimer formation of secreted LCN2
with MMP-9 was determined by gelatin zymography, and LCN2 expression was measured by western blot analysis, RT-PCR, and qRT-PCR. *P b 0.05 and ***P b 0.001 vs. the HSA-treated
control. (B) The growth rates of HSA- or AGE-treatedHASMCswere estimated using a Countess Automated Cell Counter. *Pb0.05 vs. theHSA-treated control. (C) HASMCswere cultured in
the upper transwell chamber and treatedwithHSA (200μg/mL) or AGEs (200μg/mL) in serum-freemedium for 24h. Themigrated cells on the underside of the transwellmembranewere
counted under a microscope. * P b 0.05 vs. the HSA-treated control.
3389T.-W. Chung et al. / Biochimica et Biophysica Acta 1833 (2013) 3386–3395Next, we conﬁrmed whether C/EBPβ is responsible for the
transcriptional activation of LCN2. ChIP assay data revealed that the
binding of C/EBPβ to the LCN2 promoter was remarkably increased by
AGE treatment. However, the binding afﬁnity of p65 and c-fos was not
increased by AGE treatment (Fig. 3D). The promoter assay also showed
that the transcriptional activity of the LCN2 promoter was signiﬁcantly
increased by AGE treatment (Fig. 3E). To investigate which of the
2 C/EBPβ binding sites were responsible for these observations,
we performed the promoter assay using site-directed mutants of
the C/EBPβ binding sites. The results showed that the C/EBP-2 site
was responsible for transcriptional activation of AGE-stimulated LCN2
expression in HASMCs (Fig. 3F). In addition, to verify whether C/EBPβ
functions as a transcription factor for LCN2 expression in AGE-treated
HASMCs, we knocked down C/EBPβ gene expression using shC/EBPβ
lentiviral vectors and then examined the LCN2 promoter activity. As
shown in Fig. 3G, AGEs affected transcriptional regulation of the LCN2
gene via the C/EBPβ transcription factor.3.4. Knockdown of LCN2 expression blocks AGE-elicited migration of
HASMCs but does not affect proliferation
To investigate the biological function of LCN2 elicited by AGE
treatment, we knocked down LCN2 gene expression using shLCN2
lentiviral vectors. Among 10 HASMC clones transfected with shLCN2,
the knockdown efﬁciency of LCN2 gene expression in 3 clones was
conﬁrmed by gelatin zymography, western blot analysis, RT-PCR, and
qRT-PCR (Fig. 4A). We used a single clone, clone no. 6, for further
experiments.
Because previous reports [7,11] and our data (Fig. 1B) showed that
AGEs stimulate the proliferation andmigration of HASMCs, we examinedthe possibility that the proliferation increase of AGE-treated HASMCs is
related to LCN2 expression. Our data showed that knockdown of LCN2
expression did not affect AGE-stimulated proliferation of HASMCs
(Fig. 4B). The results from the cell cycle analysis also did not show
any signiﬁcant change by LCN2 gene knockdown (Fig. 4C). These
results suggest that LCN2 expression enhanced by AGE treatment is
not responsible for the proliferation of HASMCs.
Previous studies have reported that LCN2 expression is related to the
migration and invasion of cancer cells by enhancing their motility and
sustaining MMP-9 activity [44,45]. In addition, our results (Fig. 1C)
and previous reports [42,46] showed that AGEs increase the migratory
activity of HASMCs. Thus, we investigated the effect of AGE-induced
LCN2 expression on the migration and invasion of HASMCs. Our results
showed that knockdown of LCN2 gene expression reduced the invasion
and migration of AGE-stimulated HASMCs (Fig. 5A–C). Moreover, the
results from confocal microscopic observation showed that shLCN2
suppressed AGE-induced recruitment of paxillin to focal adhesions
and polymerization of F-actin (Fig. 5D). These data suggest that AGE-
induced LCN2 gene expression plays a crucial role in the invasion and
migration of HASMCs (Fig. 6).4. Discussion
AGEs resulting from the spontaneous non-enzymatic glycosylation
of proteins are related to the removal of senescent proteins in normal
aging processes [9,47]. However, excessive AGE formation is involved
in the increase of atherosclerosis under a prolonged hyperglycemic
condition [2,40]. Several reports have shown that AGEs increase the
proliferation andmigration of VSMCs through diverse signaling pathways
[7,11,42,46]. The proteolytic activity of secreted MMPs regulates the
Fig. 2. Examination of the signaling pathways involved in AGE-induced LCN2 expression. (A, B) AGE-stimulated HASMCs were treated with an isotypic anti-IgG antibody, anti-RAGE
antibody (A), DPI, or NAC (B) in serum-free medium for 24 h. HSA was used for the control. LCN2 expression was evaluated by RT-PCR and western blot analysis. (C, D) The
phosphorylation of AGE-related signaling molecules, including Akt, JNK, ERK, and p38, was examined by western blot analysis. (E) HASMCs were treated with AGEs, LY294002,
SP600125, SB203580, U0126, and/or BAY 11-7082. HSA was used as control. LCN2 expression was evaluated by western blot analysis, RT-PCR, and qRT-PCR. #P b 0.05 vs. the untreated
control. *P b 0.05 and ***P b 0.001 vs. the AGE-treated control.
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Fig. 3. Transcriptional activity of C/EBPβ on the LCN2 promoter as measured by ChIP and promoter assays. (A) The sequence from 1kb upstream to 100bp downstream of the human
LCN2 transcription site (+1). Potential transcription factor binding sites are underlined and labeled, as identiﬁed by searching the TRANSFAC database. Boxed regions indicate two
potential C/EBPβ binding sites. The sequences of themutated C/EBPβ binding sites are shown under the box. The two primers pairs used for promoter cloning and ChIP assay are indicated
by the arrowed underline. (B) After cytoplasmic and nuclear protein extraction, the nuclear translocation of p65, c-jun, c-fos, and C/EBPβ elicited by AGE stimulation was examined by
western blot analysis. (C) HASMCs were treated with AGEs (200 μg/mL) for 12 h. The translocation of C/EBPβ into the nucleus was evaluated by immunoﬂuorescence staining with an
antibody against C/EBPβ. (D) HASMCs were treated with AGEs (200 μg/mL) for 24 h, and then cell lysates were subjected to a ChIP assay. DNA bound to C/EBPβ, the p65 subunit of NF-κB,
and c-fos was precipitated with speciﬁc antibodies. An isotypic IgG was used for exclusion of nonspeciﬁc immunoprecipitation. Precipitated and input genomic DNAs were ampliﬁed by
PCR. (E, F) HASMCs were cotransfected with a plasmid harboring different forms of the LCN2 promoter and pCMV-β-galactosidase reporter plasmids. The transfected cells were cultured
for 24 h and then treated with AGEs. At 24 h after AGE stimulation, the cells were harvested for luciferase assays. *P b 0.05 compared the indicated two groups. (G) The shC/EBPβ vector
was introduced into HASMCs, followed by selection of clones. pLKO.1 vector-harboring HASMCs were used for the control. HASMCs harboring pLKO.1 or shC/EBPβ vector were cotransfected
with a plasmid harboring different forms of the LCN2 promoter and pCMV-β-galactosidase reporter plasmids. The transfected cells were cultured for 24h and then treatedwith AGEs. At 24h
after AGE stimulation, the cells were harvested for luciferase assays. ***P b 0.001 compared with the indicated two groups.
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enhance the expression of MMP-9 via activation of ERK, p38, and NF-κB
in the murine macrophage cell line RAW264.7 and human keratinocyte
HaCaT cells [48,49]. Thus, we presumed that AGEs might increase the
expression and activity of MMPs, especially MMP-9, in HASMCs.
However, gelatin zymography and RT-PCR assays showed that theexpression and activity of MMP-2 and -9 were not inﬂuenced by
AGE treatment in HASMCs. Interestingly, gelatin zymography results
demonstrated that a protein band of about 130kDawith gelatinolytic
activity was increased by AGE treatment (Fig. 1A), indicating a
heterodimer of LCN2 and MMP-9 corresponding to the band [21,22].
Furthermore, the results from RT-PCR and western blot analysis revealed
Fig. 4. shLCN2 inhibits LCN2 expressionofAGE-stimulatedHASMCs anddoes not inﬂuence cell proliferation. (A) The shLCN2 vectorwas introduced intoHASMCs, followedby selection of
clones. pLKO.1 vector-harboring HASMCswere used as control. LCN2 expressionwas evaluated by gelatin zymography, western blot analysis, RT-PCR, and qRT-PCR. **Pb0.01 vs. theHSA-
treated control of the pLKO.1 group. *P b 0.05 vs. the AGE-treated control of the pLKO.1 group. (B) pLKO.1 and shLCN2 vector-harboring HASMCs were treated with HSA (200 μg/mL) or
AGEs (200μg/mL) for 24h. The growth rates of each groupwere estimated using a Countess Automated Cell Counter. * Pb0.05 comparedwith the indicated two groups. ns, no signiﬁcance.
(C) The effect of shLCN2 on cell cycle regulation of AGE-stimulated HASMCs was estimated by DNA content analysis using ﬂow cytometry.
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expression of MMP-9 was not changed by AGE treatment in HASMCs.
On the other hand, methylglyoxal, the precursor of AGEs, had no effect
on the expression of LCN2 in HASMCs (Supplementary Fig. 1).
To elucidate the molecular mechanism underlying the AGE-elicited
expression of LCN2, we examined AGE-related signaling pathways
such as RAGE, NADPH oxidase-ROS, MAP kinases, PI3K-Akt, and NF-κB
[7–9,13,42] using speciﬁc antibodies and signal inhibitors. The results
showed that RAGE-NADPH oxidase-ROS was involved in AGE-induced
LCN2 expression (Fig. 2A and B). In addition, among the AGE-related
downstream signaling molecules such as Akt, JNK, ERK, and p38, the
phosphorylation of Akt and JNK was involved in LCN2 expression. In
particular, although NF-κB is the main transcription factor responsible
for LCN2 expression in the injured rat aorta [43], inhibition of NF-κB
activity by a speciﬁc inhibitor, BAY 11-7082, had no effect on LCN2
expression (Fig. 2C–E). Thus, we considered that theremight be another
transcription factor regulating LCN2 expression.
Previous studies have shown that about 1 kb upstream from the
transcriptional start site is important for the regulation of LCN2
expression, and the promoter region of LCN2 has binding sites for
diverse transcription factors such as NF-κB, AP-1, PU.1, and C/EBPβ
[50–52]. In our analysis using the TRANSFAC database, NF-κB, AP-1,
and two C/EBPβ binding sites were found in the core region of the
LCN2 promoter (Fig. 3A). Among the nuclear translocations of these
transcription factors, only nuclear C/EBPβ was time-dependently
increased by AGE treatment (Fig. 3B). In addition, the results from the
ChIP assay and promoter assay showed that C/EBPβ is responsible for
AGE-induced expression of LCN2 (Fig. 3C–E).Although transcriptional activity of C/EBPβ is also regulated by other
signalingmolecules such as NF-κB, p38, and ERK [53,54], the expression
of LCN2 was regulated by transactivation of C/EBPβ through the
phosphorylation of Akt and JNK in AGE-stimulated HASMCs. Therefore,
the upregulation of C/EBPβ via activation of Akt and JNK might be
involved in this phenomenon [55,56]. In addition, the signaling pathways
involved in chronic inﬂammation elicited by AGEs may differ from those
involved in acute inﬂammation, such as angioplastic vascular injury [43].
Further study is indeed to elucidate the precise mechanism underlying
the differential activation of C/EBPβ.
AGEs enhance the progression of atherosclerosis by activating the
migration, proliferation, and calciﬁcation of HASMCs [11,13,42,46]. The
proliferation and migration of HASMCs were conﬁrmed by the results
shown in Fig. 1B and C. To elucidate the biological function of LCN2
expression enhanced by AGE treatment, we knocked down LCN2 gene
expression by introducing an shRNA vector. The results shown in
Figs. 4 and 5 indicated that shLCN2 decreased the migration, invasion,
and motility of AGE-stimulated HASMCs, but did not inﬂuence their
proliferation. Previously, LCN2 was reported to be a positive regulator
of proliferation in various malignant cells [18,57]. The reason for LCN2
showing no effect on the proliferation of AGE-treated HASMCs may be
the tissue speciﬁcity or differences between benign and malignant
cells. Alternatively, an elevation of ion channel activity [46,58] and
expression of Pim1 [59] might be sufﬁcient for AGE-induced proliferation
of HASMCs. However, the results evidently showed that AGE-elicited
expression of LCN2 does not relate with the proliferation of HASMCs.
LCN2 forms a heterodimeric complex withMMP-9 [21] and sustains
the gelatinolytic activity of MMP-9 by inhibiting autolytic degradation
Fig. 5.Knockdown of LCN2 expression suppresses themigration and invasion ofHASMCs. (A)HASMCswere seeded in the upper chamber of gelatin coated-transwells and treatedwithHSA
(200 μg/mL), AGEs (200 μg/mL), or AGEs and an MMP-9 inhibitor, rhTIMP-1 (5 μg/mL), in serum-free medium for 24 h. The invaded cells on the underside of the transwell membrane were
counted under amicroscope. ***Pb0.001 vs. theHSA-treated control. **Pb0.01 vs. the AGE-treated control. (B)HASMCs harboring pLKO.1 or shLCN2 vectorswere seeded in the upper chamber
of gelatin coated-transwells and treatedwithHSA (200μg/mL)orAGEs (200μg/mL) in serum-freemedium for 24h. The invaded cells on theunderside of the transwellmembranewere counted
under amicroscope. *Pb0.05 comparedwith the indicated twogroups. ns, no signiﬁcance. (C) Formigration assays, the transwell chamberwasnot coatedwith gelatin. Themigrated cells on the
underside of transwell membranewere counted under amicroscope. * Pb 0.05 comparedwith the indicated two groups. ns, no signiﬁcance. Representative images of themigration assays are
shown. (D) The effect of shLCN2 on the arrangement of paxillin, actin, and vinculin in AGE-stimulated HASMCs was observed by confocal microscopy. To detect paxillin and vinculin, the cells
were permeabilized and incubated with anti-paxillin or anti-vinculin antibodies and then a FITC-conjugated secondary antibody (green). Actin was stained with phalloidin (red).
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expressing HASMCs was related to the allosteric activation of MMP-9
activity. The enhanced invasivenessmay be the result of other proteolyticenzymes, including cysteine proteases and serine protease [60,61].
However, the results from knockdown of LCN2 expression by shRNA
revealed that LCN2 plays an important role in the invasion of HASMCs
Fig. 6. Schematic representation of the effect of LCN2 on HASMCmigration and the mechanism underlying AGE-induced LCN2 expression. The data presented in this study have shown
that AGEs induce expression of LCN2 by activating a RAGE-NADPH oxidase-ROS pathway, leading to activation of the PI3K-Akt-C/EBPβ pathway and JNK-C/EBPβ pathway in HASMCs.We
have also shown that inhibition of LCN2 expression by shLCN2 can block the AGE-induced invasive and migratory properties of HASMCs.
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disassociation and motility of cancer cells as well as their invasiveness
[44]. Our results and previous reports coordinately suggest that the
increase of LCN2 expression is responsible for the enhanced migration
and motility of AGE-treated HASMCs (Fig. 5B–D). LCN2 expression has
been detected in atherosclerotic plaques, especially in macrophages
[38,39]. However, LCN2 expression has also been demonstrated in
VSMCs and is especially high in intimal VSMCs [43]. Similar to the
murine macrophage-like RAW264.7 cells, in the human monocytic cell
line THP-1, MMP-9 expression is dose-dependently enhanced by AGE
treatment [49]. However, AGEs did not enhance the secretion or
expression of LCN2 in AGE-stimulated THP-1 cells (Supplementary
Fig. 2). Thus, we suggest that LCN2 is mainly expressed and secreted
from VSMCs in AGE-related vascular disease, thereby acting as an
inducer of VSMC migration.
5. Conclusions
Our results indicate that AGEs induce the expression of LCN2 by
activating a RAGE-NADPH oxidase-ROS pathway, leading to activation
of PI3K-Akt and JNK in HASMCs. We also found that transactivation of
C/EBPβ is crucial for AGE-elicited LCN2 expression. In addition, we
have shown that inhibition of LCN2 gene expression using shRNA can
block the AGE-induced invasive and migratory properties of HASMCs.
These results suggest that LCN2 is a novel and potent molecular target
for diagnosis and treatment of diabetic vascular complications.
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